{
    "clinical_study": {
        "@rank": "40367", 
        "arm_group": [
            {
                "arm_group_label": "Glutathione S-Transferase Theta1(GSTT1)/Mu1(GSTM1) wild/wild", 
                "arm_group_type": "Active Comparator", 
                "description": "Augmentin tablet"
            }, 
            {
                "arm_group_label": "GSTT1/GSTM1 wild/null type", 
                "arm_group_type": "Active Comparator", 
                "description": "Augmentin tablet"
            }, 
            {
                "arm_group_label": "GSTT1/GSTM1 null/wild type", 
                "arm_group_type": "Active Comparator", 
                "description": "Augmentin tablet"
            }, 
            {
                "arm_group_label": "GSTT1/GSTM1 null/null type", 
                "arm_group_type": "Active Comparator", 
                "description": "Augmentin tablet"
            }
        ], 
        "brief_summary": {
            "textblock": "This study has an open-label, one-sequence, multiple drug administration design. The purpose\n      of this study is as follows;\n\n        -  To evaluate the change of liver function according to glutathione s-transferase (GST)\n           genotype after the multiple administration of amoxicillin/clavulanate.\n\n        -  To evaluate the intrinsic metabolite, human leukocyte antigen (HLA) genotype, and\n           microRNA (miRNA) based on liver function change as the candidate biomarker for DILI."
        }, 
        "brief_title": "A Clinical Study to Explore Biomarkers for Drug-induced Liver Injury (DILI)", 
        "completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Healthy", 
        "condition_browse": {
            "mesh_term": [
                "Drug-Induced Liver Injury", 
                "Wounds and Injuries"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Subject with sufficient ability to understand the nature of the study and any hazards\n             of participating in it. Provide written informed consent after being fully informed\n             about the study procedures\n\n          2. Healthy male of female subjects aged 20 - 45 years\n\n          3. Subjects whose body mass index (BMI) in the range 18.5 kg/m2 (inclusive) - 27 kg/m2\n             (exclusive)\n\n        Exclusion Criteria:\n\n          1. Subject with clinically significant disease in liver, kidney, nerve system,\n             respiratory system, endocrine system, blood, tumor, urinary system, cardiovascular\n             system, mental disease or with medical history\n\n          2. Subject who has taken any prescribed drugs, herbal agents or crude drugs within 2\n             weeks before study drug administration\n\n          3. Subject who did blood donation during 1 months before the study or Blood donation\n             during 2 months before the study\n\n          4. Subject with presence or history of severe adverse reaction to study drug\n\n          5. Subject who cannot prevent pregnancy during the study period.\n\n          6. Female subject who are pregnant.\n\n          7. Subject who drank over 21 units/week of alcohol or subjects who would not be able to\n             stop drinking alcohol during the hospitalization\n\n          8. Subject who are Heavy smoker more than 10 cigarettes/day within 3 months prior to\n             screening or subjects who would not be able to stop smoking during the\n             hospitalization.\n\n          9. Subject judged not eligible for study participation by investigator."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "32", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 18, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02143323", 
            "org_study_id": "DILI_Healthy"
        }, 
        "intervention": {
            "arm_group_label": [
                "Glutathione S-Transferase Theta1(GSTT1)/Mu1(GSTM1) wild/wild", 
                "GSTT1/GSTM1 wild/null type", 
                "GSTT1/GSTM1 null/wild type", 
                "GSTT1/GSTM1 null/null type"
            ], 
            "intervention_name": "Augmentin tablet", 
            "intervention_type": "Drug", 
            "other_name": [
                "Experimental:   Augmentin", 
                "Augmentin 3 tablets (Amoxicilin:clavualanate=2:1) bid, for 14days"
            ]
        }, 
        "intervention_browse": {
            "mesh_term": "Amoxicillin-Potassium Clavulanate Combination"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "GST, DILI, biomarker", 
        "lastchanged_date": "May 18, 2014", 
        "location": [
            {
                "contact": {
                    "email": "jieonlee@snu.ac.kr", 
                    "last_name": "Jieon Lee", 
                    "phone": "82-2-2072-1666"
                }, 
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "Seoul National University Hospital"
                }, 
                "investigator": {
                    "last_name": "Jieon Lee", 
                    "role": "Sub-Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "jieonlee@snu.ac.kr", 
                    "last_name": "Jieon Lee", 
                    "phone": "+82-10-3223-2717"
                }, 
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "Jieon Lee"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "4", 
        "official_title": "A Clinical Study to Evaluate the Effect of Glutathion S-transferase Polymorphism on Pharmacokinetics/Pharmacodynamics After Multiple Administration of Amoxicillin/Clavulanate and Explore Biomarkers for Drug-induced Liver Injury (DILI)", 
        "overall_contact": {
            "email": "jieonlee@snu.ac.kr", 
            "last_name": "Jieon Lee", 
            "phone": "82-2-2072-1666"
        }, 
        "overall_official": {
            "affiliation": "Seoul National University Hospital", 
            "last_name": "In-Jin Jang, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Korea: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Aspartate Aminotransferase (AST)", 
                "safety_issue": "No", 
                "time_frame": "22 days"
            }, 
            {
                "measure": "Alanine Aminotransferase (ALT)", 
                "safety_issue": "No", 
                "time_frame": "22 days"
            }, 
            {
                "measure": "Alkaline phosphatase (ALP)", 
                "safety_issue": "No", 
                "time_frame": "22 days"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02143323"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Seoul National University Hospital", 
            "investigator_full_name": "In-Jin Jang, MD, PhD", 
            "investigator_title": "Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Seoul National University Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Seoul National University Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}